CAR-T Efficacy Evaluation

Our innovative gene-editing technology increases gene-editing efficiency by 10 to 20 fold, making
our custom model development process faster and more affordable for your research.

CAR-T efficacy evaluation in B-NDG mice

We have extensive experience evaluating the efficacy of CAR-T cells against multiple tumor models.  Efficacy can be readily assessed in our highly immune-deficient B-NDG mice.  Contact us to learn more and we would be happy to provide support for your next CAR-T project.

Case 1: CAR-T immunotherapy against human B cell lymphoma in B-NDG mice

Raji-Luc cells were implanted intravenously into B-NDG mice on Day 0. CAR-T cells were also intravenously injected at the time of Raji-Luc implantation. (A) Luciferase signal intensity of CAR-T cell treatment; (B) Body weight of treated B-NDG mice.

Case 2: CAR-T immunotherapy against human B cell lymphoma in B-NDG B2M KO mice




(A) Survival rate of B-NDG mice (n=5) and B-NDG B2M KO mice (n=9) after PBMC reconstitution and CAR-T therapy. (B)Total flux in B-NDG B2M KO mice treated with CAR-T1 or CAR-T2 cells. (C) Density of CAR-T cells in B-NDG B2M KO mice. These results demonstrated that CAR-T cells were amplified first to kill tumor cells, and then reduced as tumor cells were eliminated.

Our Pharmacology Service Guarantee

Click on the image to see full details.
Back to top